U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 430160.401USPC	APPLICATION NO 10/574,872
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANTS Alison Helena Goodall	
	INT'I FILING DATE October 7, 2004	GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2003/0021777	01/30/03	Harris et al.	424	94.64	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	AA	WO9817319	04/30/98	PCT		
	AB	WO9925383	05/27/99	PCT		
	AC	WO9942146	08/26/99	PCT		
	AD	WO0029028	05/25/00	PCT		
	AE	WO04045542	6/03/04	PCT		
	AF	WO04069862	08/19/04	PCT	X	
	AG	EP0618225	10/05/94	EP (+English Abstract)		

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AH	Agam G., et al. "Erythrocytes with covalently bound fibrinogen as a cellular replacement for the treatment of thrombocytopenia," *Eur. J. Clin. Invest., 22*(2):105-112, February 1992.
	AI	Beer, J.H., "Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor," *Blood, 79*(1):117-128, January 1, 1992.
	AJ	Bennett, Joel S., "Platelet-Fibrinogen Interactions," *Annals of the New York Academy of Sciences, 936*:340-354, 2001.
	AK	Blajchman, M. A., et al. "Substitutes and alternatives to platelet transfusions in thrombocytopenic patients," *Journal of Thrombosis and Haemostasis, 1*:1637-1641, July 2003.
	AL	Charo et al., "Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide," *J. Biol. Chem., 266*(3):1415-1421, January 1991.
	AM	Coller et al.,"Thromboerythrocytes In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions," *J. Clin Invest., 89(2):*546–555, February 1992.
	AN	Davies A.R., "Effects of Synthocytes™, A Novel Platelet Substitute, on Platelet Function," Congress XVII ISTH, 1999.
	AO	Davies, A.R. et al.,"Interactions of platelets with Synthocytes™, a novel platelet substitute," *Platelets, 13*(4):197-205, June 2002.

EXAMINER	DATE CONSIDERED
/Marsha Tsay/	01.14.12

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.T./

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 430160.401USPC	APPLICATION NO 10/574,872
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANTS Alison Helena Goodall	
	INT'I FILING DATE October 7, 2004	GROUP ART UNIT

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applican(s).

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	BA	Derrick, et al., "Peptide LSARLAF activates $\alpha_{IIb}\beta_3$ on resting platelets and causes resting platelet aggregate formation without platelet shape change," *Thromb Res., 89*(1):31-40, January 1, 1998.
	BB	Doolittle, "Fibrinogin and Fibrin," Haemostasis and Thromboses, p.491-513, 1994.
	BC	D'Souza et al., "A discrete sequence in a platelet integrin is involved in ligand recognition," *Nature, 350*:66 - 68, March 7 1991.
	BD	D'Souza et al., "The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the second calcium binding domain of its α subunit," *J. Biol. Chem., 265*(6): 3440-3446, February 1990.
	BE	Grunkemeier, J.M., et al. "Fibrinogen adsorption to receptor-like biomaterials made by pre-adsorbing peptides to polystyrene substrates," *Journal of Molecular Recognition, 9*(3):247-257, 1996.
	BF	Kuyas C., et al., "Isolation of human fibrinogen and its derivatives by affinity chromatography on Gly-Pro-Arg-Pro-Lys-Fractogel," *Thrombiosis and Haemostasis, 63*(3):439-444, June 28, 1990.
	BG	Levi, M. et al., "Fibrogen-Coated Albumin Microcapsules Reduce Bleeding in Severely Thrombocytopenic Rabbits," *Nature Medicine, 5*(1):107-111, January 1999.
	BH	Moskowitz et al., "Fibrinogen coating density affects the conformation of immobilized fibrinogen: implications for platelet adhesion and spreading," *Thromb Haemost., 79*(4):824-830, 1998.
	BI	Perkins et al., "Human biodistribution of an ultrasound contrast agent (Quantison™) by radiolabelling and gamma scintigraphy," *The British Journal of Radiology, 70*(834):603-611, 1997.
	BJ	Steiner et al., "Peptides derived from a sequence within β_3 integrin bind to platelet $\alpha_{IIb}\beta_3$ (GPIIb-IIIa) and inhibit ligand binding," *J. Biol. Chem., 268*(10): 6870-6873, April 5, 1993.
	BK	Taylor et al., "A peptide corresponding to GPIIb$_\alpha$ 300-312, a presumptive fibrinogen γchain binding site on the platelet integrin GPIIb/IIIa, inhibits the adhesion of platelets to at least four adhesive ligands," *J. Biol. Chem.,267(17):*11729-11733, June 1992.
	BL	Ware et al., "Structure of the fibrinogen gamma-chain integrin binding and factor XIIIa cross-linking sites obtained through carrier protein driven crystallization," *Protein Science, 8*(12):2663-2671, 1999.

EXAMINER	/Marsha Tsay/	DATE CONSIDERED	01.14.12

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.T./